Biogen has revealed it will acquire Apellis Pharmaceuticals for an upfront payment of approximately $5.6 billion and a contingent value right (CVR) per share payable upon achievement of certain thresholds. Apellis stockholders will receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for Syfovre. The acquisition […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!